Argus reiterated their buy rating on shares of Pfizer (NYSE:PFE) in a research report sent to investors on Wednesday morning, Analyst Ratings News reports. The firm currently has a $35.00 price target on the stock. Pfizer Inc. (NYSE:PFE) stock opened at $30.40 in last session, and closed at $30.82, while the day range of stock is $30.21 – $30.85. The stock showed a negative weekly performance of -0.61%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) traded lower after news that ARIAD has granted Specialised Therapeutics Australia Pty Ltd (STA) exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $7.77, in last session and closed at $7.84, by gaining 3.16%. The 52 week range of the stock is $2.15 – $23.00. Company’s market capitalization is $1.46 billion.
Drugmaker Merck & Co. Inc. (NYSE:MRK) is joining two dozen other pharmaceutical companies and contract laboratories in committing to ending research on chimpanzees. Merck & Co., Inc. (NYSE:MRK) stock advanced 2.49% and finished the last session at $53.51. The EPS of the stock remained 1.51. Company’s market capitalization is $156.60 billion.
Zacks downgraded shares of Gilead Sciences (NASDAQ:GILD) from an outperform rating to a neutral rating in a research note released on Wednesday morning, AnalystRatingsNetwork.com reports. They currently have $85.00 target price on the stock. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $80.70, and closed the session at $81.52. The 52 week range of the stock remained $39.24 – $84.40 and the day range was $80.65 – $82.20.